KDNY Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 rugp. 2023 @ 23:00):

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases...

Stats
Šios dienos apimtis	3.28M
Vidutinė apimtis	2.04M
Rinkos kapitalizacija	2.71B
EPS	$0 ( 2024-02-26 )
Kita pelno data	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.47
ATR14	$0.453 (1.12%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Thomas Dolca	Sell	13 300	Common Stock
2023-08-11	Thomas Dolca	Sell	23 522	Stock Option (Right to Buy)
2023-08-11	Thomas Dolca	Sell	5 948	Stock Option (Right to Buy)
2023-08-11	Thomas Dolca	Sell	13 300	Stock Option (Right to Buy)
2023-08-11	Oxtoby Andrew	Sell	160 000	Stock Option (Right to Buy)

INSIDER POWER
-96.02
Last 99 transactions
Buy: 289 232 \| Sell: 10 194 260

Tūris Koreliacija

Ilgas: 0.28 (neutral)

Trumpas: 0.00 (neutral)

Signal:(78.495) Neutral

Aduro Biotech Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
COLL	0.876
GLMD	0.873
BCDA	0.868
EVER	0.865
EEIQ	0.86
CNXC	0.86
ATIF	0.857
AGNC	0.856
ABIO	0.853
DADA	0.848

10 Labiausiai neigiamai susiję koreliacijos
RMRM	-0.904
MTEK	-0.902
APR	-0.88
APP	-0.859
MMAC	-0.857
NGMS	-0.85
AAPL	-0.845
RBKB	-0.843
RIBT	-0.842
COUP	-0.841

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aduro Biotech Inc Koreliacija - Valiuta/Žaliavos

0.34
( neutral )

0.51
( weak )

0.84
( strong )

0.75
( moderate )

0.51
( weak )

-0.41
( neutral )

Aduro Biotech Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$6.13M
Bruto pelnas:	$4.41M (71.90 %)
EPS:	$-2.87

FY	2022
Pajamos:	$6.13M
Bruto pelnas:	$4.41M (71.90 %)
EPS:	$-2.87

FY	2021
Pajamos:	$51 625.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00226

FY	2020
Pajamos:	$827 000
Bruto pelnas:	$827 000 (100.00 %)
EPS:	$-6.20

Financial Reports:

No articles found.

Aduro Biotech Inc

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Realaus laiko atnaujinimai Aduro Biotech Inc [KDNY]

Upcoming Earnings Alert